

Please add the following new claims:

45. (New) The process of claim 1 wherein the cell culture medium comprises hydrocortisone.
46. (New) The process of claim 1 wherein the cell culture medium comprises human serum.

### **Remarks**

Reconsideration and withdrawal of the rejections of the claims, in view of the amendments and remarks herein, is respectfully requested. Claims 1 and 8-9 are amended, and claim 45-46 are added. Claims 1-46 are pending. The amendments are intended to further prosecution and are not intended to concede to the correctness of the Examiner's position or to prejudice the prosecution of the claims prior to amendment, which claims are present in a continuation of the present application.

Amended claims 1, 8 and 9 are supported by originally-filed claims 1, 8 and 9, respectively.

New claim 45 is supported at page 16, line 25 of the specification.

New claim 46 is supported at page 6, line 6 of the specification.

### **The 35 U.S.C. § 112 Rejections**

The Examiner rejected claims 1-14 and 44 under 35 U.S.C. § 112, second paragraph, as being indefinite. The amendments to the claims render the § 112(2) rejections moot. Accordingly, withdrawal of the § 112(2) rejections is respectfully requested.

### **The 35 U.S.C. § 102 Rejections**

The Examiner rejected claim 44 under 35 U.S.C. § 102(b) as being anticipated by Asahara et al. (Science, 275, 964 (1997)) or Levine et al. (U.S. Patent No. 5,132,223). These rejections are respectfully traversed.